These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Sherertz T; Wallner K; Wang H; Sutlief S; Russell K Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1241-5. PubMed ID: 11728683 [TBL] [Abstract][Full Text] [Related]
7. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. Terk MD; Stock RG; Stone NN J Urol; 1998 Oct; 160(4):1379-82. PubMed ID: 9751358 [TBL] [Abstract][Full Text] [Related]
12. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy. Thomas C; Keyes M; Liu M; Moravan V Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357 [TBL] [Abstract][Full Text] [Related]
13. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy. Lee HK; Adams MT; Shi Q; Basillote J; Lamonica J; Miranda L; Motta J Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1445-9. PubMed ID: 19553032 [TBL] [Abstract][Full Text] [Related]
14. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Elshaikh MA; Angermeier K; Ulchaker JC; Klein EA; Chidel MA; Mahoney S; Wilkinson DA; Reddy CA; Ciezki JP Urology; 2003 Jan; 61(1):152-5. PubMed ID: 12559287 [TBL] [Abstract][Full Text] [Related]
15. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Thomas MD; Cormack R; Tempany CM; Kumar S; Manola J; Schneider L; Hurwitz MD; D'Amico AV Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):905-8. PubMed ID: 10863058 [TBL] [Abstract][Full Text] [Related]
16. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study. Salem N; Simonian-Sauve M; Rosello R; Alzieu C; Gravis G; Maraninchi D; Bladou F Radiother Oncol; 2003 Feb; 66(2):159-65. PubMed ID: 12648787 [TBL] [Abstract][Full Text] [Related]
17. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310 [TBL] [Abstract][Full Text] [Related]
18. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149 [TBL] [Abstract][Full Text] [Related]
19. The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. Crook J; Toi A; McLean M; Pond G Brachytherapy; 2002; 1(3):131-7. PubMed ID: 15090275 [TBL] [Abstract][Full Text] [Related]
20. Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer. Mierzwa ML; Barrett WL; Redmond K; Shirazi R; Kastl A; Kumar N; Buncher R Cancer; 2008 Nov; 113(9):2605-9. PubMed ID: 18816596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]